stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.28
0.38
+2.73%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Debt to equity
Biohaven Ltd.'s debt to equity at the end of the quarter to 30 September 2026 was −2.7×, down 7.3× from fiscal 2025 (4.6×). Over the past ten years it has ranged from −33.4× (fiscal 2019) to 4.6× (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 4.6× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.1× | (29.53%) |
| FY2021 | 0.1× | — |
| FY2020 | −0.7× | — |
| FY2019 | −33.4× | — |
| FY2018 | 0.8× | — |
| FY2017 | 0.0× | — |
| FY2016 | −0.3× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | −2.7× | — |
| Jun 2026 | 21.2× | 1,036.54% |
| Mar 2026 | 1.9× | (59.28%) |
| Dec 2025 | 4.6× | — |
| 39 more quarters | Free account |
Against its own ten years
Low −33.4×
High 4.6×
Ten-year median
0.0×
Current reading's percentile
100
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| BHVN Biohaven Ltd. | −2.7× |
| PVLA Palvella Therapeutics, Inc. compare | 0.0× |
| ADMA ADMA Biologics Inc compare | 0.0× |
| VCEL Vericel Corporation compare | 0.0× |
| IMNM Immunome, Inc. compare | 0.0× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| CLDX Celldex Therapeutics, Inc. compare | 0.0× |
| AUPH Aurinia Pharmaceuticals Inc compare | 0.1× |
| VERA Vera Therapeutics, Inc. compare | 0.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)